Yes $2.40 ACET secondary./
Adicet Bio's new preclinical data highlighting ADI-270 selected for ASGCT
Ok this is damn interesting they kind of did present: With an oral followup on the 10th!!!!!
In my experience when some good news is not properly received by a stock that co will often add a little something extra to the oral.. Stoney loves a little extra with the oral!!!!!
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models
ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment
On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024
Preclinical data will be featured in oral presentation on May 10, 2024
REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Apr. 22, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place fromMay 7-11, 2024, inBaltimore, MD. The oral presentation will take place onMay 10, 2024in the Targeted Gene andCell Therapysession, co-chaired by Adicet Bio’s Chief Scientific Officer,Blake Aftab, Ph.D.
